Merck's Recall of Rofecoxib — A Strategic Perspective
F. Oberholzer-Gee
and
S. N. Inamdar
- 18 Nov, 2004
This article requires a subscription.
Login via Athens or your institution
Already a print subscriber? Activate your online access
Not a Subscriber?
